How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

VBWG ACC 2017 Dr. Rajagopalan considers how the emergence of GLP-1 agonists, DPP-4 inhibitors and SGLT2 inhibitors has caused a sea change in the mangement of diabetes towards a broader approach to address CV risk.

Educational information

This video was recorded after the Vascular Biology Working Group Meeting at ACC 2017, in Washington, DC, USA.

PACE-cme did not receive financial support for the production of this video.

Disclosures

Sanjay Rajagopalan, MD - Case Western Reserve School of Medicine, Cleveland, OH, USA

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.